Latanoprost Neon Healthcare (Latanoprost)

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the ciliary body. Activation of these receptors triggers a signaling cascade that increases uveoscleral outflow of aqueous humor, thereby lowering intra‑ocular pressure. The effect is achieved with once‑daily topical administration.

The dosing regimen for Latanoprost Neon Healthcare is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once each evening, but the exact dose and frequency should follow the individual prescriber’s instructions and the product label.

Safety data for latanoprost in pregnancy and lactation are limited. It is classified as a precautionary medication; it should only be used when the potential benefit outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential before use.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers potent intra‑ocular pressure reduction with once‑daily dosing. Compared with beta‑blocker eye drops, it often provides greater pressure‑lowering efficacy and a more favorable systemic safety profile, though individual response may vary.

The product should be stored at room temperature, below 25 °C, in its original packaging. It must be kept away from direct sunlight, moisture and extreme temperatures to maintain stability and potency throughout its shelf life.

Latanoprost is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the prescribed eye(s). The eye should be closed gently for a few minutes to aid absorption, and contact lenses should be removed before instillation.

Although rare, serious adverse events can include uveitis, corneal edema, and sudden vision loss. Patients should be instructed to seek immediate medical attention if they experience eye pain, redness, blurred vision, or any sudden change in visual acuity while using the medication.

Latanoprost is contraindicated in individuals with known hypersensitivity to latanoprost or any component of the formulation. Caution is also advised for patients with active ocular inflammation, recent ocular surgery, or those who are pregnant or breastfeeding without a clear benefit‑risk assessment.